On July 3, 2024, iBio Inc, a biotechnology company incorporated in Delaware, announced the entry into an At Market Issuance Sales Agreement (ATM Agreement) with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC. The agreement allows iBio to sell shares of its common stock from time to time through these sales agents. The offering is contingent upon the effectiveness of iBio's shelf registration statement on Form S-3, filed with the SEC on the same date. The company has set parameters for the sale, including the number of shares, the time period for sales, daily sales limits, and minimum sale price. The sales agents will sell the shares as defined by Rule 415(a)(4) on the NYSE American or any other...Show More

On July 3, 2024, iBio Inc, a biotechnology company incorporated in Delaware, announced the entry into an At Market Issuance Sales Agreement (ATM Agreement) with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC. The agreement allows iBio to sell shares of its common stock from time to time through these sales agents. The offering is contingent upon the effectiveness of iBio's shelf registration statement on Form S-3, filed with the SEC on the same date. The company has set parameters for the sale, including the number of shares, the time period for sales, daily sales limits, and minimum sale price. The sales agents will sell the shares as defined by Rule 415(a)(4) on the NYSE American or any other trading market for the stock, with the possibility of privately negotiated transactions with the company's approval. iBio is not obligated to sell any shares and may suspend offers at any time, while the sales agents are not required to purchase shares. The sales agents will receive up to a 3.0% commission on gross proceeds from sales and are entitled to indemnification and reimbursement for certain expenses. The offering will end upon the sale of all shares under the agreement or if the agreement is terminated.